A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2018
At a glance
- Drugs ACH 4471 (Primary)
- Indications Glomerulonephritis; Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacokinetics
- Sponsors Achillion Pharmaceuticals
- 25 May 2018 Status changed from active, no longer recruiting to completed.
- 26 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2017 According to an Achillion Pharmaceuticals media release, interim results from this trial are anticipated during the second quarter of 2018.